ArticleCell reports. Medicine2026
Hierarchically collapsible nanoactuator modulates mitochondrial ferroptosis-bioenergetic homeostasis cascade to decouple ischemic stroke.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke, a life-altering cerebrovascular emergency triggered by prolonged cerebral hypoperfusion, remains a therapeutic enigma. Current interventions struggle with ischemia-reperfusion injury; restoring blood flow unleashes reactive oxygen species (ROS), driving secondary neuronal damage and functional loss. Ischemia-induced mitochondrial dysfunction heightens oxidative stress and hastens neuronal death. We address oxidative-stress-driven neuronal injury by engineering a hierarchically collapsible nanoactuator suppressing mitochondrial ferroptosis and restoring cellular energy homeostasis. The nanoactuator integrates a diselenide-crosslinked shell conjugated with a mitochondrial-targeting peptide, enabling blood-brain barrier penetration and mitochondrial delivery. Its collapsible core, composed of an ATP-gadolinium coordination polymer encapsulating a ferroptosis inhibitor, enables MRI-guided tracking and ROS-responsive drug release. In damaged mitochondria, the nanoactuator replenishes ATP, restores membrane potential, reduces ROS levels, and alleviates ferroptosis. Intravenous administration in a transient middle cerebral artery occlusion (tMCAO) mouse model demonstrated robust multi-mechanistic neuroprotection. This hierarchical nanoactuator platform offers a strategy for ischemic stroke and related neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.